Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours

BACKGROUND: Dulanermin (rhApo2L/TRAIL) induces apoptosis by binding to death receptors DR4 and DR5, leading to caspase activation and subsequent cell death. A Phase1a trial evaluated the safety and tolerability of dulanermin in patients with advanced tumours. One aim was to develop and validate phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Y, Xu, R, Peach, M, Huang, C-P, Branstetter, D, Novotny, W, Herbst, R S, Eckhardt, S G, Holland, P M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251880/
https://www.ncbi.nlm.nih.gov/pubmed/22033270
http://dx.doi.org/10.1038/bjc.2011.456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251880/
https://www.ncbi.nlm.nih.gov/pubmed/22033270
http://dx.doi.org/10.1038/bjc.2011.456

Ejemplares similares